Dr.
Fairclough current research interests include the design and analysis of
longitudinal studies of Quality of Life with non-random missing data due to disease
morbidity or mortality. She has recently published a book entitled “Design and
Analysis of Quality of Life Research in Clinical Trials” and has published over
100 publications on topics related to Quality of Life and psychosocial sequelae
of cancer and its therapy in pediatric and adult patients.
Fairclough DL. Design and Analysis of Quality of Life Studies in Clinical Trials.
Chapman and Hall/CRC Press, Boca Raton, Florida, 2002.
Cella D, Eton DT, Fairclough DL, et al. ‘What is a clinically
meaningful change on the Functional Assessment of Cancer Therapy- Lung (FACT-L)
Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study
5592. J Clin Epi.35:285-295, 2002.
Sloan J, Aaronson N, Cappelleri J, Fairclough D,
Varricchio C, and the Clinical Significance Consensus Meeting Group. Assessing
the clinical significance of single items relative to summated scores. Mayo
Clinic Proc 2002, in press.
Revicki DA, Osoba D, Fairclough
D, Barofsky I, Berzon R, Leidy NK, Rothman M. Recommendations on health-related quality of life research to
support labeling and promotional claims in the United States. Quality of Life Research 9:887-900,
2000.
Fairclough DL, Fetting JH, Cella D,
Wonson W, Moinpour CM. Quality of Life and Quality Adjusted Survival for breast
cancer patients receiving Adjuvant Therapy. Quality of Life Research, 8:723-731,
1999.
Fairclough DL. Quality of Life, Cancer
Investigation and Clinical Practice. Cancer Investigation. 16: 478-484,
1998.
Fairclough DL, Cella DF. Functional
assessment of cancer therapy (FACT-G): non-response to individual questions. Quality
of Life Research 1996; 5:321-329.
Fairclough DL, Cella DF. A Cooperative
Group Report on Quality of Life Research: Lessons Learned. Eastern Cooperative
Oncology Group (ECOG). J Natl Cancer Instit 1996; 40:73-75.
In recent
years, Dr. Fairclough has been extensively involved in exploring analytic
methods for longitudinal studies with non-random missing data. This has
included the examination of multiple imputation techniques, mixed-effects
selection models and mixture models. As a results of collaborative efforts with
major cancer cooperative groups (ECOG, IBCSG) and other consulting responsibilities,
she has access to a number of large randomized trials to examine the
performance of various methods in realistic settings.
Fairclough DL. Design and Analysis of Quality of Life Studies in Clinical Trials.
Chapman and Hall/CRC Press, Boca Raton, Florida, 2002.
Fairclough DL, Peterson H, Chang V. Why
are missing quality of life data a problem in clinical trials of therapy for
cancer? Stat Med. 1998; 17:667-677.
Troxel AB, Fairclough DL,
Curren D, Hahn EA. Statistical Analysis of Quality of Life with missing data in
cancer clinical trials. Statistics in Medicine. 1998;17:653-666
Fairclough DL, Peterson HF, Cella D,
Bonomi P. Comparison of Several Model-Based Methods for Analyzing Incomplete
Quality of Life Data in Cancer Clinical Trials. Stats Med. 1998; 17:781-796.
Fairclough DL. Summary measures and
statistics for comparison of quality of life in a clinical trial of cancer
therapy. Stat Med 1997;16:1197-1209.
Fairclough DL, Gelber R.
"Statistical Issues and Considerations" in Quality of Life and
Pharmacoeconomics in Clinical Trials, ed Spliker B., Raven Press, 1996;
427-435.
Fairclough DL. Quality of Life in Cancer
Clinical Trials: Now That We Have the Data, What Do We Do? J Appl Stat Sci 1996;4(4):253-269.
Fairclough DL. "Methods of analysis
for longitudinal studies of health-related quality of life". In
"Quality of Life Assessment in Clinical Trials: Methods and
Practice". Ed Staquet MJ, Hayes RD, Fayers PM, Oxford University Press,
1998; 227-248.
Fairclough DL, Schwertman NC. Estimation of a positive definite general dispersion matrix from repeated measures with missing data: A Monte Carlo Comparison of the EM Algorithm, Smoothing, and Use of Complete Data Vectors. J Statist Comput Simul. 1994; 50:21-27.
Dr.
Fairclough is currently a member of the Pediatric Adaptation to Pediatric
Cancer (PACC) collaboration and directs their Data management and Statistics
Core. These investigations include interventions for the mothers and siblings
of newly diagnosed pediatric cancer patients, children with cognitive
impairments, bereaved mothers, and pediatric oncology nurses. Included in this
are methodological investigations of mediational models. Dr. Fairclough also is
a co-investigator on several of the Eastern Cooperative Group trials
investigating quality of life in patients with advanced cancer.
Sahler OJZ, Varni JW, Fairclough
DL, et al. Problem Solving Skills Traing for Mothers of Children with Newly
Diagnosed Cancer; A Randomized Trial. J Dev Behav Pediatr 23:77-86,2002.
Elkin TD, Phipps S, Mulhern
RK, Fairclough DL. Psychological functioning of adolescent and young
adult survivors of pediatric malignancy. Med Pediatr Oncol.
1997;29(6):582-588.
Patenaude AF, Basili L, Fairclough
DL, Li FP. Attitudes of 47 mothers of pediatric oncology patients toward
genetic testing for cancer predisposition. J Clin Oncol 1996;
14:415-421.
Fairclough DL. The effects of a support
group on selected psychosocial outcomes of bereaved parents whose child died
from cancer, commentary. J Pediatr Oncol Nurs 1995; 12:59-61.
Waber DP, Tarbell NJ, Fairclough
DL, Atmore K, Castro R, Isquith P, Lussier F, Romero I, Carpenter PJ,
Schiller M, Sallan SE. Cognitive sequelae of treatment in childhood acute
lymphoblastic leukemia: cranial radiation requires an accomplice! J Clin
Oncol 1995; 15: 2490-2496.
Phipps S, Fairclough DL,
Mulhern RK. Avoidant coping in children with cancer. J Pediatric Psych
1995; 20:217-32.
Mulhern RK, Fairclough DL,
Smith B, Douglas SM. Maternal depression, assessment methods and physical
symptom affect estimates of depression symptomatology among children with
cancer. J Ped Psych 1992; 17:313-326.
Ochs J, Mulhern R, Fairclough
DL, Parvey L, Whitaker J, Ch'ien L, Mauer A, Simone J. Comparison of
neuropsychologic functioning and clinical indicators of neurotoxicity in
long-term survivors of childhood leukemia given cranial radiation or parenteral
methotrexate: A prospective study. J Clin Oncol 1991; 9:145-151.
Mulhern RK, Fairclough DL, Ochs J. A prospective comparison of neuropsychological performance of children surviving leukemia who received 18 Gy; 24 Gy or no cranial irradiation. J Clin Oncol 1991; 9:1348-1356.